CompletedPhase 1/2

Allopurinol and Pathogenesis of Cirrhosis

Egypt100 participantsStarted 2023-06-01

Plain-language summary

Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age 18-75 both sex Exclusion Criteria: * active GIT bleeding

What they're measuring

biomarkers as zonulin, LPS, MMP-13, MDA

Timeframe: 6 MONTHS

Trial details

NCT IDNCT07033533

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Cirrhoses, Liver trials